SELLAS Life Sciences Group (SLS)
Develops licensed oncology candidates GPS and SLS009 for cancer indications.
$11.66
vs last close−0.36 (−3.00%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 8 | 10 | 8 | 7 | 7 | 6 | 7 | 7 | 8 | 9 | 11 | |
| Research & development | 6 | 5 | 5 | 5 | 4 | 4 | 3 | 4 | 4 | 5 | 5 | 6 |
| 4 | 3 | 5 | 2 | 3 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | |
| General & administrative | 4 | 3 | 5 | 2 | 3 | 2 | 3 | 3 | 3 | 4 | 4 | 4 |
| Operating income | −9 | −8 | −10 | −8 | −7 | −7 | −6 | −7 | −7 | −8 | −9 | −11 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 |
| Income before tax | −9 | −8 | −10 | −7 | −7 | −7 | −6 | −7 | −7 | −8 | −8 | −10 |
| Net income from continuing operations | −9 | −8 | −10 | −7 | −7 | −7 | −6 | −7 | −7 | −8 | −8 | −10 |
| Net income | −9 | −8 | −10 | −7 | −7 | −7 | −6 | −7 | −7 | −8 | −8 | −10 |
| EPS, basic | −$0.33 | −$0.26 | −$0.21 | −$0.13 | −$0.10 | −$0.09 | −$0.07 | −$0.07 | −$0.06 | −$0.05 | −$0.05 | −$0.05 |
| EPS, diluted | −$0.33 | −$0.26 | −$0.21 | −$0.13 | −$0.10 | −$0.09 | −$0.07 | −$0.07 | −$0.06 | −$0.05 | −$0.05 | −$0.05 |
| Weighted average shares, basic | 28 | 31 | 45 | 57 | 68 | 74 | 88 | 94 | 108 | 153 | 172 | 189 |
| Weighted average shares, diluted | 28 | 31 | 45 | 58 | 68 | 74 | 88 | 99 | 108 | 153 | 172 | 189 |
| EBITDA | −9 | −8 | −10 | −7 | −7 | −7 | −6 | −7 | 0 | −8 | −8 | −10 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| EBIT | −9 | −8 | −10 | −7 | −7 | −7 | −6 | −7 | −7 | −8 | −8 | −10 |